Optimizing Polymyxin B Therapy in Critical Care: Pharmacokinetic Insights and Clinical Outcomes in a Retrospective Cohort Study
PMB pharmacokinetics are closely related to patient outcomes. An AUCss, 24 h ≥ 81.6 mg·h/l may reduce mortality. Baseline eGFR and PMB treatment duration are independent risk factors for AKI during PMB therapy.
Authors
- Maggie Xiong
- Jianfeng Xie (ORCID: https://orcid.org/0000-0002-6097-9172)
- A. Zhong (ORCID: https://orcid.org/0000-0002-3137-9987)
- Shuai Liu (ORCID: https://orcid.org/0000-0001-8732-9754)
- Jie He (ORCID: https://orcid.org/0000-0002-2734-1644)
- Yingzi Huang (ORCID: https://orcid.org/0000-0001-8304-3580)
- Chen Zhang (ORCID: https://orcid.org/0009-0009-0288-9484)
- Qing Li (ORCID: https://orcid.org/0000-0002-0169-8098)
- Haofei Wang (ORCID: https://orcid.org/0000-0003-2845-7558)
- Linlin Hu (ORCID: https://orcid.org/0000-0002-7545-5195)
- Mengyao Bi (ORCID: https://orcid.org/0009-0000-8497-4600)
- Q. Peng
Institutions
- Zhongda Hospital Southeast University (CN)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-09-20
- DOI
- https://doi.org/10.1007/s40121-025-01213-3
- Citations
- 1
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 1.39